Alnylam制药公司获得价格目标高的买价评级,表明股票可能增长。 Alnylam Pharmaceuticals receives buy ratings with high price targets, indicating potential stock growth.

Alnylam制药公司是一家以RNA干扰疗法为重点的生物制药公司,它获得了Redburn大西洋公司的“买”评级和353美元的价格目标,表明其潜在收益率为31.49%。 Alnylam Pharmaceuticals, a biopharmaceutical company focusing on RNA interference therapies, has received a "buy" rating and a $353 price target from Redburn Atlantic, indicating a 31.49% potential upside. 股票价格目标也从Stifel Nicolaus提升至345美元, The stock also got a price target boost from Stifel Nicolaus to $345, suggesting a 28.51% rise. Alnylam公司目前的市场上限为349.2亿美元,分析家预测该年的EPS为-1.7 EPS。 Alnylam's current market cap is $34.92 billion, and analysts predict a -1.7 EPS for the year.